Morning All,
Yes we are all disappointed with the current SP, while we await the verdict from the DSMB on REMAP-CAP & news on CLARITY 2.0.
It was not the CCR2 inhibitor DMX-200 that was identified as a safety concern in critically unwell COVID-19 patients that caused the RAS Domain to be halted.
We have previously discussed why ACEi & ARBs can be an issue in critically unwell patients in ICU, so not going to re-hash that. Just waiting on word from the DSMB.
A lot of interesting research on CCR2 coming out. Please read this & then tell me we are not pioneering a potential treatment here for not only SARS COV2 but other respiratory infections as well.
https://pubmed.ncbi.nlm.nih.gov/34749524/https://www.news-medical.net/news/20211115/SARS-CoV-2-infection-inhibited-by-CCR2-signaling.aspxhttps://dimerix.com/products/dmx-200-for-covid-pneumonia/And atherosclerosis (this is just an abstract, but I will try & get the full article, as of interest to us).
https://academic.oup.com/eurheartj/advance-article-abstract/doi/10.1093/eurheartj/ehac094/6543079?redirectedFrom=fulltext&login=falseAfter reading the above articles, I am starting to wonder IF it’s possible that DMX-200 may be restarted as a Monotherapy (ie without ARB) in the severe arm of REMAP-CAP? This is just a thought guys, but a lot of evidence out there.
The Moderate disease RAS arms were suspended temporarily until full DSMB review. From the REMAP-CAP website & the ANN, there did not appear to be any safety concerns identified there, but they need to take a cautionary approach.
The current sentiment here from a few does remind me of the 7-8c days, & that was made harder by a few posters here with their day in & day out negatively & sledging Nina & the BOD. I see it’s back, great timing to rub some salt into LTH’s wounds. I refuse to take this BS onboard.
I have Stormer on ignore because he was doing the same on another stock. It doesn’t add to any form of constructive discussion on our pipeline or IP, and that is really what matters most in the long run, and possibly even in the shorter term with the body of evidence growing, not just in COVID-19, but cardio-renal disease for CCR2 as a target for treatment.
@Malzo I know you were talking about me when you mentioned “Spruikers” on this board & it’s not the first time you have implied that I’m Nina Webster. That is just ridiculous. I have been invested in DXB long before Nina was CEO.
I’m not going to report your post, because it just demonstrates what little understanding you have of this company & reflecting your own paranoia onto others.
Personally I think Nina is doing a great job of running Dimerix, getting us through to Ph3 trials and facilitating 2 large Ph3 independently run International trials for a small Australian biotech & attracting millions in Govt Funding & attracting some very internationally renowned Nephrologists, Respiratory Physicians & Renal trial specialists to our Medical Advisory Board, who are also Lead Investigators on Big Pharma trials for SLGT2i & DKD/CKD.
Tell me why they would be interested in Dimerix trialing DMX-200 if they didn’t think there was something super interesting here in a CCR2 inhibitor?
I have a lot of respect for Nina & I do hope to be in the same Australian State & room as her one day to meet her personally. I haven’t felt the need to email lately, because results & recommendations from the DSMB from external trials will be made available to us when disclosed to DXB.
Some good posts there
@Eqz, thank you. Nina Webster doesn’t push the sell button for people lol, 100% right in that each of us is responsible for our own investment decisions. I
find the ‘pointing the finger thing’ very immature & it usually comes from those who don’t DYOR. Biotechs are a long game, if you can’t handle the heat, get out of the kitchen. There has been a lot of stock manipulation going on recently & shorting in biotechs, helped along by Macro market happenings & Investor fear & panic. Shame to the ones adding to that on HC. You know who you are.
Have a good weekend All